Many types of cancer cells are resistant to Fas-mediated apoptosis by several mechanisms, including the mutations of the genes involved in Fas-mediated apoptosis. In this study, to explore the possibility that the mutations of the genes involved in the proximal pathway of Fas-mediated apoptosis (Fas, FADD, caspase 8 and caspase 10) are involved in cancer metastasis, we have analysed somatic mutation and deletion of these genes in 80 non-small cell lung cancers (NSCLCs) with (n=43) and without (n=37) metastasis to the regional lymph nodes. We found 12 mutations (four Fas, four FADD, and four caspase 10 mutations) in 11 of 80 NSCLCs (13.8%). Interestingly, of these mutations, most mutations (10 out of 12) were detected in the NSCLCs with metastasis, and the frequency in the metastasis lesions (23%) was higher than that in the primary lesions of the NSCLCs without metastasis (5.4%). Furthermore, transfection study revealed that the tumor-derived mutants have decreased apoptosis inductions compared to the wild types. These data suggest that the inactivating mutations of the genes in the proximal pathway of Fas-mediated apoptosis may lead to a decreased cancer cell death and play a role in the metastasis of NSCLC.
Introduction
Apoptosis is one of the most important regulatory mechanisms of tissue homeostasis in organisms (Nagata, 1997) . Cells from human malignancies have a reduced capability to undergo apoptosis in response to some physiological stimuli Nagata, 1997) . This may contribute to tumorigenesis, to further growth of a malignancy and to metastasis . Recent reports showed that highly metastatic cells exhibited a superior survival ability and resistance to apoptosis compared to poorly metastatic cells . It has been reported that metastatic and nonmetastatic cells diered in their susceptibility to Fas-mediated apoptosis as a major pathway for the induction of apoptosis in cells and tissues Owen-Schaub et al., 1998; Maeda et al., 1999) , indicating that metastatic cancer cells may have much more dysregulations in apoptosis pathways, especially in Fas-mediated apoptosis. However, the molecular and genetic basis for the association of aggressive metastatic phenotype with resistance toward apoptosis remains to be elucidated.
Stimulation of Fas results in aggregation of its intracellular death domains (DD), leading to the recruitment of two key signaling proteins that together with the receptor form the death-inducing signaling complex (DISC) (Kischkel et al., 1995) .
FADD/MORT-1 (Chinnaiyan et al., 1995) couples through its C-terminal DD to cross-linked Fas receptors and recruits caspase 8 (Boldin et al., 1996) through its N-terminal death eector domain (DED) to the DISC. Caspase 10 (Mch4/FLICE2) is a caspase homologous to caspase 8 and is present as an inactive proenzyme comprising a prodomain that contains two DEDs to allow caspase 10 to interact with the DED of FADD and a catalytic protease domain that can be further processed to give a large and a small subunit (Wang et al., 1999) . The local aggregation of the procaspases 8 and 10 is sucient to allow autoprocessing or transprocessing to produce active caspases 8 and 10, which can subsequently activate downstream executioners, such as caspases 3 and 7 (Wang et al., 1999) .
Fas is widely expressed in normal and neoplastic cells (LeithaÈ user et al., 1993) , but the expression of this protein does not necessarily predict susceptibility to killing (Natoli et al., 1995) . This can re¯ect the presence of inhibiting mechanisms of Fas-mediated apoptosis. The Fas-mediated apoptosis can be blocked by several mechanisms, including the alterations of the genes involved in this pathway (Nagata, 1997) . Interestingly, Fas mutations have been detected in several types of human cancers, including NSCLC with frequent allelic losses of chromosome 10q23 ± 24 where Fas gene resides (Lee et al., 1999a,b; Shin et al., 1999) . Therefore, it can be hypothesized that other members involved in Fas-mediated apoptosis are mutated in the cancers with frequent allelic losses at the chromosome where the candidate genes reside. Allelic loss of chromosome 11q 13.3 where FADD resides, and allelic loss of 2q33-34 where caspase 8 and caspase 10 reside, have been reported as frequent events in NSCLC (Chan et al., 1996; Petersen et al., 2000) , but the mutational studies of FADD, caspase 8 and caspase 10 genes in NSCLC have not yet been reported. Furthermore, the incidence of loss of heterozygosity (LOH) on 2q33-34 and 10q23-24 was signi®cantly more often in the metastatic NSCLCs (Petersen et al., 2000) , suggesting the presence of several tumor suppressor genes in these loci and the association of the possible tumor suppressor genes with the progression of NSCLC.
In the present study, to explore the possibility that the alterations of the genes involved in the proximal events of Fas-mediated apoptosis pathway might play a role in the progression of NSCLC to regional lymph node metastasis, we analysed a series of 80 NSCLCs with or without metastasis for detection of genetic alteration of the Fas, FADD, capase 8 and caspase 10 genes.
Results

Mutations of Fas, FADD, caspase 8 and caspase 10 genes
Through the microdissection technique, we selectively procured tumor cells from the histologial sections of 80 NSCLCs, as shown previously (Lee et al., 1999a,b; Shin et al., 1999) . Genomic DNA was isolated and analysed for potential mutations of all exons of Fas, FADD, caspase 8 and caspase 10 genes by polymerase chain reaction (PCR)-single strand conformation polymorphism (SSCP) analysis. Enrichment and sequence analysis of aberrantly migrating bands led to the identi®cation of 12 mutations in 11 of the 80 samples (13.8%) ( Table 1 ). The mutations were found in Fas (n=4), FADD (n=4), and caspase 10 (n=4), but not in caspase 8. One tumor (case 29) was found to have both Fas and caspase 10 mutations. None of the corresponding normal samples showed evidence of mutations by SSCP (Figure 1 ), indicating that the mutations detected in the NSCLC specimen had risen somatically. As for the relationship between the presence of metastasis and the mutations, 10 of the 12 mutations were found in the NSCLCs with regional lymph node metastasis (23% of 43 NSCLCs with metastasis), while two mutations were found in the NSCLCs without metastasis (5.4% of 37 NSCLCs without metastsis) (Table 1) , and statistically, there was a signi®cant dierence in the mutation frequency of the NSCLCs with metastasis and without metastasis (Fisher's exact test, two tails, P=0.03). Nine of the 10 mutations detected in metastatic NSCLCs were observed only in metastatic lesions, while the remaining one mutation (case 40) was observed both in primary and metastatic cancers (Table 1) . Among the four Fas gene mutations, two mutations in metastatic lesions were detected in exon 9 encoding the DD of Fas. Among the four FADD gene mutations, three were detected in exon 1 encoding the DED of FADD.
As for the relationship between the histologic types and the mutations, all of the four caspase 10 mutations and the three FADD mutations found in the metastatic NSCLCs were detected only in adenocarcinoma, but it was not statistically signi®cant (Fisher's exact test, two tails, P40.05). As for the relationship between the stages and the mutations, the 11 cases with the mutations consisted of two stage I, seven stage II and two stage III NSCLCs. There was a signi®cant dierence between the mutation frequencies in the stage I and stage II NSCLCs (Fisher's exact test, two tails, P50.05).
Allelic status
The LOH frequencies at chromosome 10q23-24 for Fas, 11q13.3 for FADD and 2q33-34 regions for caspase 8 and caspase 10, were examined using microsatellite markers or intragenic polymorphic markers (Table 2 ). Compared to the NSCLCs without metastasis, the metastatic lesions of the NSCLCs with metastasis showed higher incidence of allelic losses in all loci examined. However, of the three loci, the allelic loss at chromosome 2q33-34 was statistically higher in the metastatic lesions of the NSCLCs than in the NSCLCs without metastasis (Fisher's exact test, two tails, P=0.02), suggesting chromosome 2q33-34 region might be involved in the progression of NSCLC to metastasis. In the 11 cases with the mutations, eight tumors showed LOH for one or more polymorphic marker(s) for the corresponding mutated genes ( Table  2) .
Abrogation of apoptosis activities by Fas, FADD and caspase 10 mutations
To determine whether the mutant forms of Fas, FADD and caspase 10 detected are functionally defective, we generated Fas, FADD, and caspase 10 mammalian expression constructs containing the cDNAs with the mutations found in this study by using site-directed mutagenesis. We con®rmed expression of the wild types, and mutants of the Fas, FADD and caspase 10 by Western blotting (data not shown). On transfection into human embryonic kidney 293 cells, we found that all Fas, FADD and caspase 10 mutant types showed a signi®cantly decreased apoptosis compared to the cells 
Discussion
Metastasis, a biologic hallmark of malignant tumors, is a major cause of cancer-related morbidity and mortality. The frequency of metastasis of lung cancer varies slightly with the histologic pattern but averages greater than 50%, and most lung cancer patients succumb to metastasis (Kobzik, 1999) . There have been evidences that dysregulation of apoptosis is involved in the mechanisms of metastasis Owen-Schaub et al., 1998; Maeda et al., 1999) . For example, a Fas gene mutation was detected not in the primary tumor, but in the metastatic foci of adult T cell leukemia (Maeda et al., 1999) . In order to explore genetic basis for the dierences between primary NSCLC and metastatic NSCLC, we analysed somatic mutations of the genes involved in the proximal events of Fas-mediated apoptosis (Fas, FADD, caspase 8 and caspase 10), and found 12 mutations in Fas, FADD and caspase 10 genes ( Table 2 ). The higher mutation frequency in the metastases than that in the corresponding primary tumors (23% versus 5.4%) indicates that the mutation of genes in the Fas-pathway play an important role in the metastasis of NSCLC.
Although we do not actually know whether NSCLC is resistant to Fas-mediated apoptosis in vivo, our data support the idea that NSCLC cells may be resistant to Fas-mediated apoptosis. It is well known that the location of mutation domain is important to predict the function of the mutants. The DD in the Fas is evolutionarily highly conserved and is shown to be necessary and sucient for the transduction of an apoptotic signal (Nagata, 1997) . Also, most of the somatic mutations of Fas detected in the previous reports are located in the DD. The DED in FADD is essential for the recruitment of caspases 8 and 10 to activate Fas signaling (Nagata, 1997) . The small and large subunits of caspase 10 are important for its protease function. The location of the detected mutations in the DD of Fas (cases 3 and 7), the DED of FADD (cases 23, 41 and 55), the p17 large subunit in caspase 10 (cases 29 and 30) and the p12 small subunit in caspase 10 (cases 36 and 40) supports the idea that the mutants act as apoptosis blockers in Fas pathway. Furthermore, the decreased induction of apoptosis by the overexpression of the mutants compared to the wild-types (Figure 2) indicates that Fas-mediated apoptosis in these tumors may contribute the increased survival of the tumor cells. The immunohistochemistry revealed that most of the NSCLCs expressed Fas, FADD and caspase 10. Furthermore, all of the NSCLCs with the mutations of Fas or FADD or caspase 10 showed coexpression of Fas, FADD and caspase 10, suggesting that mutated Fas, FADD and caspase 10 are expressed, but that these mutants might construct an abnormal DISC, which might block the apoptosis signals.
Of the four genes analysed for somatic mutations in the present study, we detected mutations in Fas, FADD and caspase 10, not in caspase 8 (Table 2) . Fas mutation was reported in NSCLC by our previous study (Lee et al., 1999a) . A laryngeal squamous cell carcinoma was reported to have the somatic mutation Figure 2 Defective apoptotic activities of tumor-derived Fas, FADD and caspase 10 mutants. Twenty-four hours after the transfection of the wild-type Fas vector or the mutant-type Fas vectors, 48 h after the transfection of the wild-type FADD vector or the mutant-type vectors, or 48 h after the transfection of the wild-type caspase 10 vector or the mutant-type caspase 10 vectors, human embryonic kidney 293 cells were ®xed in 10% methanol for 15 min and stained with 1 mg/ml DAPI for 15 min, and the nuclei were examined under¯uorescence microscopy (mean+s.d.:n=4) of caspase 8 (Mandruzzato et al., 1997) . Germline mutation of caspase 10 was reported in autoimmune lymphoproliferative syndrome type II (Wang et al., 1999) . Until now, somatic mutations of caspase 10 and FADD in human cancer have not yet been reported. Our study is the ®rst report to detect somatic mutations of caspase 10 and FADD and clearly, attempt to ®nd potential mutations of these genes in other cancers is needed in the future studies.
In addition of genetic alteration, epigenetic modi®ca-tion of caspase 8 by DNA methylation has recently been implied in loss of caspase 8 function in several solid tumors of childhood (Fulda et al., 2001) . Absence of caspase 8 mutation in this study led us to analyse the methylation status of the NSCLCs. However, the quantity of genomic DNA from the metastatic NSCLCs used in this study were too small to be analysed in methylation study. Instead, we analysed the methylation of caspase 8 in another series of frozen NSCLC tissues (n=50), but methylation speci®c PCR revealed that none of caspase 8 DNA was hypermethylated in these NSCLCs (HS Kim and NJ Yoo, unpublished), indicating caspase 8 in NSCLC may not be inactivated at least by mutation and methylation.
To be metastasized, cancer cells should escape from the immune attack from lymphoid cells. It has been known that most lung cancer cells express Fas (Lee et al., 1999a) . Therefore, metastatic NSCLC cells may have Fas-resistance mechanisms such as mutations of Fas pathway genes to escape immune attack during the progression. Because tumor necrosis factor-related apoptosis-inducing ligand receptors 1 and 2 genes, and other death receptors, are mutated in metastatic breast cancers (Shin et al., 2001) , the mutation of genes in the death receptor pathway might represent a mechanism underlying tumor metastasis. It is also conceivable that the mutation of these genes could be used as a tumor marker for metastasis in the future.
Materials and methods
Tissue samples and microdissection
Formalin-®xed and paran-embedded archival tissues of human NSCLC with (n=43) or without (n=37) the regional lymph node metastasis were obtained from 80 surgically treated patients. The NSCLCs with the metastasis consisted of 22 squamous cell carcinomas and 21 adenocarcinomas, and the NSCLCs without the metastasis consisted of 15 squamous cell carcinomas, 15 adenocarcinomas and seven bronchioloalveolar carcinomas. The cancers consisted of 37 stage I, 29 stage II, and 14 stage III NSCLCs. Malignant cells and normal cells were selectively procured from hematoxylin and eosin-stained slides using a 30G1/2 hypodermic needle (Becton Dickinson, Franklin Lakes, NJ, USA) axed to a micromanipulator, as described previously (Lee et al., 1998) . DNA extraction was performed by a modi®ed single-step DNA extraction method (Lee et al., 1998) .
Single strand conformation polymorphism (SSCP) analysis
Genomic DNA each from tumor cells or corresponding normal cells was ampli®ed with primer pairs covering the entire coding region of the Fas (Lee et al., 1999a) , FADD, caspase 8 and caspase 10 genes (Table 1) . Numbering of cDNA of Fas, FADD, caspase 8 and caspase 10 (Genbank accession No. M67454, X84709, X98172 and AC007283, respectively) was done in respect to the ATG start codon. Each PCR reaction was performed under standard conditions in a 10 ml reaction mixture containing 1 ml of template DNA, 0.5 mM of each primer, 0.2 mM of each deoxynucleotide triphosphate, 1.5 mM MgCl 2 , 0.4 unit of AmpliTaq Gold polymerase (Perkin-Elmer, Foster City, CA, USA), 0.5 mCi of [ 32 P]dCTP (Amersham, Buckinghamshire, UK), and 1 ml of 106 buer. The reaction mixture was denatured for 12 min at 948C and incubated for 35 cycles (denaturing for 30 s at 948C, annealing for 30 s at 50 ± 608C and extending for 30 s at 728C). Final extension was continued for 5 min at 728C. After ampli®cation, PCR products were denatured 5 min at 958C at a 1 : 1 dilution of sample buer containing 98% formamide/5 mmol/L NaOH and were loaded onto a SSCP gel (FMC Mutation Detection Enhancement system; Intermountain Scienti®c, Kaysville, UT, USA) with 10% glycerol. After electrophoresis, the gels were transferred to 3 mm Whatman paper and dried and autoradiography was performed with Kodak X-OMAT ®lm (Eastman Kodak, Rochester, NY, USA). For the detection of mutations, DNAs showing mobility shifts were cut out from the dried gel, and re-ampli®ed for 35 cycles using the same primer set. Sequencing of the PCR products was carried out using the cyclic sequencing kit (Perkin-Elmer, Foster City, CA, USA) according to the manufacturer's recommendation.
LOH analysis
Tumor DNA or corresponding normal DNA from each slide were ampli®ed with six microsatellite markers (Research Genetic, Huntsville, AL, USA), including D2S1366, D2S116, and D2S317 in chromosome 2q33-34, and D11S4139, D11S1314 and D11S987 in chromosome 11q13.3. The known polymorphic sites at positions 71377 (promoter region) and 7670 (promoter region) in Fas gene were also examined for the LOH studies of Fas. The PCR and SSCP conditions of LOH study were the same with the condition described above. Complete or nearly complete absence of one allele in tumor DNA of informative cases, as de®ned by direct visualization, was considered as LOH.
Site-directed mutagenesis
Site-directed mutagenesis was performed using a Quick Change Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacture's instructions. To change a base, plasmids that contained the full-length cDNA of Fas, FADD or caspase 10 genes in pcDNA3.1-HA (Invitrogen, Carlsbad, CA, USA) were used as a template. The sequences of the mutagenized plasmids were con®rmed after the site-directed mutagenesis.
Cell culture, transfection and apoptosis assay
Human embryonic kidney 293 cells were maintained in EMEM (Bio Whittaker, Walkersville, MD, USA) supplemented with 10% FBS, 1 mM L-glutamine and antibiotics. 293 cells (10 6 ) were plated per well in two chamber slide and transfected by the Superfect Transfection Reagent (Qiagen, 
Immunohistochemistry
Antibody for human Fas (C-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA), antibody for human FADD (N-18, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and antibody for human caspase 10 (C-16, Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used to detect Fas, FADD and caspase 10 on tissue sections. Immunohistochemical procedures were performed as described previously (Lee et al., 1999a) . Tumors were interpreted as positive by immunohistochemistry when at least weak to moderate cytoplasmic staining was seen in greater than 30% of the neoplastic cells. The results were reviewed independently by two pathologists.
